Journal Report

CNS Drugs

Download PDF
Journal Information
Journal Title
CNS Drugs
Publisher
Adis
ISSN
1172-7047
E-ISSN
1179-1934
Database
SCOPUS
Domain
Health Sciences, Life Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Parental Cardiometabolic History, Family Income, and Cardiometabolic Risk in Antipsychotic-Treated Children, Adolescents, and Young Adults: A Nationwide Cohort Study
Mikkel Højlund, Rikke Wesselhoeft, Anne Katrine Pagsberg et al.
2026-10-10
DOI: 10.1007/s40263-026-01338-0
A Phase 3, Multicenter, Randomized, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Tolerability of Serdexmethylphenidate/d-Methylphenidate Capsules in Chinese Children with Attention-Deficit/Hyperactivity Disorder
Jing Liu, Ying Yang, Yi Wang et al.
2026-10-4
DOI: 10.1007/s40263-026-01341-5
Cognitive Effects of Cenobamate as Compared to Perampanel: A Cross-Sectional Multicentre Study in 600 Patients
Juri-Alexander Witt, Judit Catalán-Aguilar, Elisa Schütz et al.
2026-10-2
DOI: 10.1007/s40263-026-01340-6
Eculizumab and Ravulizumab During Pregnancy in Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis: Balancing Maternal Disease Control and Fetal Safety
Eva Dhupia, Jennifer A. McCombe, Sean J. Pittock et al.
2026-9-30
DOI: 10.1007/s40263-026-01339-z
Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis
Aisling McGuigan, Hannah A. Blair
2026-9-30 Vol. 40 Issue 11 Pages 1547-1559
DOI: 10.1007/s40263-026-01335-3
Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials
Itai Danovitch, Kyla Truman, Haze Brown et al.
2026-9-23 Vol. 40 Issue 11 Pages 1481-1511
DOI: 10.1007/s40263-026-01334-4
From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer’s Disease
Robert Perneczky, Frank Jessen, Timo Grimmer et al.
2026-9-15
DOI: 10.1007/s40263-026-01333-5
Bistromathics in Epilepsy and the Relativity of Numbers
Emilio Russo, Roberta Roberti, Eugen Trinka
2026-9-11 Vol. 40 Issue 11 Pages 1421-1427
DOI: 10.1007/s40263-026-01336-2
Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents
Marco Mula
2026-9-9 Vol. 40 Issue 11 Pages 1445-1458
DOI: 10.1007/s40263-026-01331-7
Correction: Efficacy and Safety of an Early Aggressive Lipid‑Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy
Ho Geol Woo, Jaeyu Park, Tae-Jin Song et al.
2026-9-4 Vol. 40 Issue 11 Pages 1561-1561
DOI: 10.1007/s40263-026-01332-6
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 3, 2026 05:35